Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
CA 2446408 C · Owner: The United States Of America, As Represented By The U.S. Department Of Veterans Affairs · Inventors: Burrows, Gregory G.; Vandenbark, Arthur A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Two-domain MHC polypeptides useful for manipulation of antigen-specific Tcells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked .beta.1 and .alpha.1 domains and MHC class I-, based molecules that comprise covalently linked .alpha.1 and .alpha.2 domains. These polypeptides may also include covalently linked antigenic determinants toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells and are useful, among other things, to detect and purify antigen-specific T-celles to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 1, 2002 and granted October 29, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 1, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 1, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.